Neonc Technologies Holdings, Inc.

Neonc Technologies Holdings, Inc.

NTHI·NASDAQ

$4.35

-4.2%
HealthcareBiotechnology

Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.

At a Glance

Live Snapshot
Market Cap$86.98M
EPS-3.2300
P/E Ratio-1.35
Earnings Date06/03/2026

nthi

Short Term Debt

Last Annual Value

5.95M

3-Year CAGR

392%

5-Year CAGR

39%

10-Year CAGR

18%

Neonc Technologies Holdings, Inc.

Neonc Technologies Holdings, Inc. Competitors Analysis of Short Term Debt

NTHI · NASDAQ
CompanyShort Term Debt
CAGR 3Y
CAGR 5Y
CAGR 10Y
5.95M
-3.4%39.0%N/A 
4.56M
N/AN/A19.0%
IVVD logo
Invivyd, Inc.
NASDAQ:IVVD
1.31M
N/AN/AN/A
OABI logo
OmniAb, Inc.
NASDAQ:OABI
3.88M
N/AN/AN/A
544.00K
N/A22.4%-10.8%
569.00K
N/AN/AN/A
0.00
N/AN/AN/A
427.00K
N/A-41.4%N/A
0.00
N/AN/AN/A
1.24M
N/AN/AN/A
751.00K
N/A-17.8%N/A
Neonc Technologies Holdings, Inc.

Neonc Technologies Holdings, Inc. Fair Value Envelope

NTHI · NASDAQ

Our analysis suggests that NTHI has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.35, this represents a potential HIDDEN relative to our calculated worth for Neonc Technologies Holdings, Inc..

Intrinsic Value
Current Price: $4.35